Torrent Pharmaceuticals Share Price Today (TORNTPHARM)
TORNTPHARM Today's Stock View
Torrent Pharmaceuticals closed up 2.29% at ₹4,768.3. With a market cap of ₹1.58 L Cr., it trades at a P/E of 72.95. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
Torrent Pharmaceuticals Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Torrent Pharmaceuticals Limited, framed against the sector median so the premium or discount is obvious at a glance.
Torrent Pharmaceuticals Limited trades at a P/E of 72.95× and P/B of 18.81×, against the Healthcare sector median P/E of 38.67×.
Valuation
Profitability
Growth
Financial Health
Torrent Pharmaceuticals Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Torrent Pharmaceuticals Limited — derived from the live tape, not yesterday's close.
Torrent Pharmaceuticals Limited last traded at ₹4,768.3 with an intraday range of ₹4,680–₹4,783 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹4768.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 5013.53 | +245.23 | +5.14% |
| R3 | 4910.53 | +142.23 | +2.98% |
| R2 | 4846.77 | +78.47 | +1.65% |
| R1 | 4807.53 | +39.23 | +0.82% |
| PIVOT | 4743.77 | -24.53 | -0.51% |
| CURRENT | 4768.30 | — | — |
| S1 | 4704.53 | -63.77 | -1.34% |
| S2 | 4640.77 | -127.53 | -2.67% |
| S3 | 4601.53 | -166.77 | -3.50% |
| S4 | 4498.53 | -269.77 | -5.66% |
TORNTPHARM is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹4680–₹4729.7
Trading Above opening range, showing Bullishness
Torrent Pharmaceuticals Limited financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Torrent Pharmaceuticals Limited, switchable between annual and quarterly views, consolidated or standalone.
Torrent Pharmaceuticals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹1.58 L Cr. and reported EPS of ₹64.04.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 6,002 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 |
| Other Income | 299 | 57 | 122 | 57 | 197 | 45 | 58 | 23 | -94 |
| Total Income | 6,301 | 7,730 | 8,061 | 8,062 | 8,705 | 9,665 | 10,786 | 11,539 | 13,886 |
| Cost of Goods Sold (COGS) | 1,674 | 2,219 | 2,167 | 2,147 | 2,443 | 2,735 | 2,686 | 2,776 | 3,388 |
| Gross Profit | 4,328 | 5,454 | 5,772 | 5,858 | 6,065 | 6,885 | 8,042 | 8,740 | 10,592 |
| +Operating Expenses | 2,979 | 3,470 | 3,602 | 3,373 | 3,634 | 4,043 | 4,674 | 5,019 | 6,033 |
| EBITDA | 1,349 | 1,984 | 2,170 | 2,485 | 2,431 | 2,842 | 3,368 | 3,721 | 4,559 |
| +Non-Operating Expenses | 717 | 765 | 1,105 | 1,016 | 432 | 1,040 | 1,250 | 1,023 | 1,415 |
| Profit Before Tax (PBT) | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,673 | 2,872 |
| +Tax Expense | 253 | 126 | 162 | 274 | 449 | 602 | 696 | 762 | 734 |
| Total Profit for Period | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,138 |
| Less: Non-controlling Interests | — | — | — | — | — | — | — | — | -25 |
| Net Profit (Owner's PAT) | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,163 |
| Earnings Per Share (EPS) | 20.03 | 12.88 | 30.29 | 36.99 | 22.96 | 36.79 | 48.93 | 56.46 | 63.91 |
| Diluted Shares Outstanding (Nos.) | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 | 34 |
| +Additional Disclosures | 6,903 | 9,063 | 8,849 | 8,783 | 9,449 | 10,416 | 11,225 | 11,525 | 14,108 |
| Sales Growth % | — | 27.84 | 3.47 | 0.83 | 6.28 | 13.07 | 11.52 | 7.35 | 21.40 |
| YoY Sales Growth % | — | 27.84 | 3.47 | 0.83 | 6.28 | 13.07 | 11.52 | 7.35 | 21.40 |
| Material Cost % | 17 | 17 | 17 | 18 | 18 | 15 | 15 | 13 | 13 |
| Employee Cost % | 19 | 18 | 18 | 18 | 18 | 17 | 18 | 19 | 19 |
| Other Cost % | 31 | 27 | 27 | 24 | 25 | 25 | 25 | 24 | 24 |
| OPM % | 22 | 26 | 27 | 31 | 29 | 30 | 31 | 32 | 33 |
| Tax % | 27 | 22 | 14 | 18 | 37 | 33 | 30 | 29 | 26 |
| Profit Growth % | — | -35.69 | 135.09 | 22.15 | -37.94 | 60.23 | 33.01 | 15.40 | 13.19 |
| Gross Margin % | 72.11 | 71.08 | 72.70 | 73.18 | 71.29 | 71.57 | 74.96 | 75.89 | 75.77 |
| EBITDA Margin % | 22.48 | 25.86 | 27.33 | 31.04 | 28.57 | 29.54 | 31.39 | 32.31 | 32.61 |
| Interest Coverage Ratio | 3.05 | 2.71 | 3.36 | 5.10 | 6.94 | 6.41 | 7.23 | 11.61 | 8.94 |
| Ebit | 940 | 1,366 | 1,516 | 1,827 | 1,769 | 2,135 | 2,560 | 2,926 | 3,440 |
Torrent Pharmaceuticals segment analysis: revenue and profit mix.
Disclosed business segments at Torrent Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Torrent Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Torrent Pharmaceuticals Limited.
Our AI distills the core fundamental drivers supporting Torrent Pharmaceuticals Limited, the risks that threaten it, and the exact valuation or growth triggers that should make you re-evaluate.
Torrent Pharmaceuticals Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
TTM revenue grew 41.8% YoY, demonstrating strong sales momentum and market traction.
Operating margin 25.01% TTM reflects robust pricing power and operational efficiency.
ROE 27.4% significantly exceeds peer median 14%, indicating superior capital deployment.
Promoter holding 68.31% signals strong founder commitment and long-term strategic alignment.
FII holdings increased from 10.8% to 16.1%, reflecting growing institutional confidence.
Key Risks.
Latest quarterly EPS declined 21.9% YoY despite revenue growth, signaling earnings pressure.
TTM EPS declined 21.7% YoY, indicating persistent profitability challenges year-over-year.
P/E ratio 68.6x far exceeds peer median 30x, suggesting significant overvaluation.
Total debt ₹0.15 LCr with D/E 0.85x indicates moderate leverage requiring monitoring.
Payout ratio 69.01% limits reinvestment capacity for future growth initiatives.
Flip Conditions.
Trim if P/E re-rates above 95 (~2.5× the sector multiple of 38.7). The valuation cushion thins from there.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.35. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 12%. The operating engine is no longer compounding capital efficiently.
Torrent Pharmaceuticals Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Torrent Pharmaceuticals Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
Torrent Pharmaceuticals Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Torrent Pharmaceuticals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Torrent Pharmaceuticals Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Torrent Pharmaceuticals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Torrent Pharmaceuticals Limited stood at 44.3% of traded volume, against a 20-day average of 54.9%.
Torrent Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings Torrent Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Torrent Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 148 documents below.
Trading Window
Torrent Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Disclosure under SEBI Takeover Regulations
Torrent Investments Limited (formerly known as Torrent Investments Private Limited) has Submitted to the Exchange a copy of Disclosure under…
Analysts/Institutional Investor Meet/Con. Call Updates
Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Copy of Newspaper Publication
Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication - Newspaper Advertisement - Intimation of the 53rd AGM…
Outcome of Board Meeting
Torrent Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 22, 2026.
Investor decks & rating reports.
Torrent Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Torrent Pharmaceuticals has declared, sequenced by announce and record date.
Torrent Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Torrent Pharmaceuticals Limited: business, sector, key facts.
What Torrent Pharmaceuticals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Torrent Pharmaceuticals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: TORNTPHARM, BSE: 500420.
Torrent Pharmaceuticals Limited is a global pharmaceutical company headquartered in Ahmedabad, India, with a significant presence in several key international markets including the United States, Brazil, and Germany. The company's core business focuses on the research, development, manufacturing, and marketing of generic pharmaceutical formulations. This means they produce and sell less expensive versions of brand-name drugs once their patents have expired, making them accessible to a wider patient population.
Their product portfolio spans a broad range of therapeutic areas, addressing diverse health needs. Key areas of focus include cardiovascular health (treating heart conditions), central nervous system disorders (affecting the brain and nerves), gastrointestinal issues (relating to the digestive system), and women's healthcare. Beyond these core areas, they also offer products in dermatology (skin conditions), diabetology (diabetes management), pain management, gynecology, oncology (cancer treatment), and anti-infective medications (fighting infections). They also produce and distribute vitamins, minerals, and nutritional supplements.
In addition to its own branded products, Torrent Pharmaceuticals also provides contract manufacturing services. This means the company manufactures pharmaceuticals for other companies, leveraging its established manufacturing capabilities and expertise to provide a service to the broader pharmaceutical industry. This diversification contributes to the company's overall revenue streams and operational stability.
With a history dating back to 1959, Torrent Pharmaceuticals, formerly known as Trinity Laboratories, has established itself as a prominent player in the global generic pharmaceutical market. Its operations extend across multiple continents, demonstrating a successful international expansion strategy. The company is a subsidiary of Torrent Investments Private Limited, reflecting its position within a larger corporate structure.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Torrent Pharmaceuticals Limited (TORNTPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Torrent Pharmaceuticals Limited (TORNTPHARM)?
The current share price of Torrent Pharmaceuticals Limited (TORNTPHARM) is ₹4,768.3. Today, the stock has gained by ₹106.90 (2.29%), trading in a range of ₹4,680 to ₹4,783. The stock opened at ₹4,680 with a trading volume of 3,45,920 shares.
02Is Torrent Pharmaceuticals Limited stock a good investment for long-term?
Torrent Pharmaceuticals Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹1,57,796.8 crores, P/E ratio of 72.95, ROE of 16.99%, and ROCE of 15.20%. The dividend yield stands at 0.94%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Torrent Pharmaceuticals Limited stock?
The 52-week high price of Torrent Pharmaceuticals Limited (TORNTPHARM) is ₹4,742.9, while the 52-week low is ₹3,287.3. Currently trading at ₹4,768.3, the stock is 101.7% away from its 52-week low and -0.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Torrent Pharmaceuticals Limited stock at the current price?
Whether to buy Torrent Pharmaceuticals Limited stock at ₹4,768.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 72.95 and P/B ratio of 18.81. Today's performance shows a gain of 2.29%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Torrent Pharmaceuticals Limited and when is the next dividend?
Torrent Pharmaceuticals Limited offers a dividend yield of 0.94%, which means for every ₹100 invested at the current price of ₹4,768.3, you can expect to receive approximately ₹0.94 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Torrent Pharmaceuticals Limited?
Torrent Pharmaceuticals Limited's key financial metrics include: P/E Ratio: 72.95, P/B Ratio: 18.81, ROE: 16.99%, ROCE: 15.20%, Dividend Yield: 0.94%, EPS: ₹64.04, Book Value: ₹247.85, and Debt-to-Equity: 0.85. The company's market cap stands at ₹1,57,796.8 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Torrent Pharmaceuticals Limited stock performing today in the market?
Torrent Pharmaceuticals Limited stock opened at ₹4,680 and is currently trading at ₹4,768.3, showing a gain of ₹106.90 (2.29%). The intraday high is ₹4,783 and low is ₹4,680. The trading volume stands at 3,45,920 shares, indicating moderate market participation today.
08What is the P/E ratio of Torrent Pharmaceuticals Limited and what does it indicate?
Torrent Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 72.95, which means investors are willing to pay ₹72.95 for every ₹1 of earnings. With an EPS of ₹64.04, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Torrent Pharmaceuticals Limited (TORNTPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.